Kolexia
Chaoui Driss Hématologie
Chaoui Driss
Hématologie
Centre Hospitalier Argenteuil
Argenteuil, France
82 Activités
192 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Leucémies Lymphomes Leucémie chronique lymphocytaire à cellules B Leucémie lymphoïde Anémie Tumeurs à plasmocytes Thrombopénie Maladie de Hodgkin

Collaborateurs

Voir plus
Al Jijakli Ahmad
Al Jijakli Ahmad
Centre Hospitalier Argenteuil, Argenteuil, France
Genet Philippe
Genet Philippe
Centre Hospitalier Argenteuil, Argenteuil, France
Andreoli Annalisa
Andreoli Annalisa
Hôpital Saint-Louis, Paris, France
Mesbah Louisa
Mesbah Louisa
Centre Hospitalier Argenteuil, Argenteuil, France

Industries

Voir plus
Amgen
13 collaboration(s)
Dernière en 2023
Roche
11 collaboration(s)
Dernière en 2023
Abbvie
10 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
9 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
Real-life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
EJHaem   13 décembre 2023
Real-World Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated before the Anti-CD38 Antibodies Era in France, the Emmy Cohort 2017 to 2020
65th ASH Annual Meeting Abstracts   02 novembre 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica   01 octobre 2023
STAIR: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia
Essai Clinique (French Innovative Leukemia Organisation)   23 mai 2023
Un objectif de 70 à 80 patients par an - Le Parisien
Le Parisien   19 avril 2023
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma
Essai Clinique (Takeda Pharmaceutical)   07 février 2023
Driss Chaoui vainqueur du 70 km du Raid-Light Vendée Trail ... - Facebook
Facebook   05 novembre 2022
IFM2014-02: IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma
Essai Clinique (Janssen)   17 mai 2022
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood   09 mai 2022
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
Blood advances   13 janvier 2022